William G Dixon

Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

William G Dixon, K. Watson, Mark Lunt et al. · Arthritis & Rheumatism · 2006 · 754 citations

Medicine, Infectious Diseases, Internal Medicine +15

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

William G Dixon, Kimme L Hyrich, Kath Watson et al. · Annals of the Rheumatic Diseases · 2009 · 710 citations · Full text

Medicine, Immunology, Pharmacotherapy +17

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

James Galloway, Kimme L Hyrich, Louise Mercer et al. · Lara D. Veeken · 2010 · 671 citations · Full text

Medicine, Immunology, Pharmacotherapy +17

The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)

Sinéad Langan, Sigrún Alba Jóhannesdóttir Schmidt, Kevin Wing et al. · BMJ · 2018 · 620 citations · Full text

Medicine, Pharmacology, Electronic Health Records +13

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register

William G Dixon, Kath Watson, Mark Lunt et al. · Arthritis & Rheumatism · 2007 · 561 citations · Full text

Medicine, Immunology, Internal Medicine +17